LONDON (Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has made progress in developing its Type 2 diabetes and inflammation treatments.
The company expects to progress both the Type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months, it said.
C4X said it has identified critical drug design principles for the treatment of type 2 diabetes which will allow it to create potent, orally-administered compounds to treat the condition.
It has also been able to identify NRF-2 pathway activators which will allow it to deliver improved efficacy and safety in inflammation treatments. The NRF-2 pathway is a key component used in treating disease like chronic obstructive pulmonary disease and multiple sclerosis.
"We continue to make outstanding progress with our proprietary programmes, which are focused on areas of high unmet medical need, with large target market. Our technology enables us to design novel, selective, potent leads and drug candidates in a fraction of the time and cost compared to conventional methods," said Chief Executive Piers Morgan.
Shares in C4X were down 0.7% to 68.00 pence on Wednesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.